Neuroendocrine Tumors Market Report- In-depth Analysis with Strong Application Scope | Novartis, Pfizer

The Neuroendocrine Tumors Market research report identifies key market trends and focuses on the significant trends and factors driving the market growth. In addition, Neuroendocrine Tumors Market analyses the global and key regions’ market potentials and advantages, opportunities and challenges, restraints and risks. Finally, the Neuroendocrine Tumors Market research report strategically analyzes each submarket concerning market growth trends and their contribution.

Get a FREE PDF Sample Copy of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4904053

Top Companies Mentioned in this Report-
Blueprint Medicines
Bristol Myers Squibb
Camurus AB
Exelixis Inc
Hutchmed
Ipsen Pharma
ITM Isotopen Technologien Munchen
Merck & Co
Novartis
Pfizer
Progenics Pharmaceuticals
Roche
Shanghai Junshi Bioscience

Neuroendocrine neoplasms are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body. Well-differentiated neuroendocrine tumors (NETs), represent the majority of NENs, and poorly differentiated neuroendocrine carcinomas (NECs), representing only 10?20% of all NENs. 62?67% of NETs occur in the gastrointestinal (GI) tract, specifically in the small intestine, appendix, and large intestine. 22?27% of NETs occur in the lungs, the second most common location of NETs, with about 30% of lung NETs occurring in the bronchial system, so-called bronchopulmonary. Approximately 7% of NETs can develop in the pancreas and 3% in the thymus.

The market of neuroendocrine cancers is facing some unique dynamics beginning in 2021. The class of somatostatin analogs is so important in the treatment of NETs that it represents approximately 55% of the global market share. In total, ~80% of this market’s value is under threat of generic competition. For this market to see true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products. With only five products in late-stage development, this is not the case and thus the market value is forecast to increase from $3.1B in 2020 to $3.4B in 2030, at a CAGR of 0.9% in the 8MM.

Key Highlights in this Report-
- The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to expansions of currently marketed therapies in new markets during the forecast period.
- The main barriers to growth in the 8MM are patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care.
- Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.
- The most important unmet needs in the ALL market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.

KEY QUESTIONS ANSWERED-
- Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
- What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
- How has the introduction of Lutathera shaped the 2nd and 3rd lines of therapy? How will the competition fare?
- What is the expected future uptake of immune checkpoint inhibitors across the 8MM?

Scope of this Report-
- Overview of Neuroendocrine Tumors including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline Neuroendocrine Tumors market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Neuroendocrine Tumor therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
- Analysis of the current and future market competition in the global Neuroendocrine Tumor therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy this Report-
Neuroendocrine Tumors Market Report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumor therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine Tumor market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global Neuroendocrine Tumor therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Discount on this Full Report @ https://www.reportsnreports.com/purchase.aspx?name=4904053

List of Tables in this Report-
Table 1: Neuroendocrine tumors: Key Metrics in the 8MM
Table 2: Grade and Proliferation Segmentation in Neuroendocrine Tumors
Table 3: Risk Factors and Comorbidities for NETs
Table 4: Treatment Guidelines for NETs
Table 5: Top 10 Deals by Value, 2011-2020
Table 6: NET Market - Global Drivers and Barriers, 2020-2030
Table 7: Key Events Impacting Sales for NETs in the US, 2020-2030
Table 8: NET Market - Drivers and Barriers in the US, 2020-2030
Table 9: Key Events Impacting Sales for NETs in the 5EU, 2020-2030
Table 10: NET Market - Drivers and Barriers in the 5EU, 2020-2030
Table 11: Key Events Impacting Sales for NETs in Japan, 2020-2030
Table 12: NET Market - Drivers and Barriers in Japan, 2020-2030
Table 13: Key Events Impacting Sales for NETs in China, 2020-2030
Table 14: NET Market - Drivers and Barriers in China, 2020-2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

ReportsnReports.com
+ 1 888 391 5441
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.